Company / Cash & Equivalents
NextCure, Inc. Cash & Equivalents History
FY2019-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$12.3M
FY2021
5-year range
$12.3M / $34.1M
FY2019-FY2021
Trend
-62.4%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $34M to $12M over the past 2 years.
Based on SEC 10-K filings.
$12M in FY2021.
Declined from $34M to $12M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, cash & equivalents decreased 62.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $12.3M | -62.4% |
| FY2020 | $32.8M | -3.9% |
| FY2019 | $34.1M | - |
As of FY2021 · SEC 10-K Annual Filings · Updated Jun 28, 2026